Memorial Sloan-Kettering Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium Jun 5, 2022 Rectal Cancer Patient Subset Shows Complete Response to Immunotherapy in Small Study Jun 3, 2022 Biodesix, Memorial Sloan Kettering Team on Minimal Residual Disease Test May 20, 2022 MSK Starts Offering Pediatric Cancer Patients Whole-Genome, Transcriptome Sequencing Premium May 20, 2022 Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics May 6, 2022 MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner Premium Apr 13, 2022 MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS' Opdivo Apr 12, 2022 In Sixth Year, Project GENIE Diversifying, Integrating Local Ancestry and Enhancing Clinical Data Premium Mar 18, 2022 Researchers ID Gut Microbiome Impact on CAR T-Cell Therapy Outcomes Premium Feb 22, 2022 CAR T-Cell Therapies Show Early Promise Against Advanced Prostate Cancer Premium Feb 18, 2022 Atara Biotherapeutics CAR T-Cell Mesothelioma Trial Paused After Patient Death Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Oct 21, 2021 MSK Fellows Develop Online Resource to Increase Awareness of Genetic Cascade Testing Premium Oct 7, 2021 FDA Recognizes Portion of MSK Oncology Knowledge Base in Public Human Genetic Variant Database Oct 5, 2021 GNS Healthcare Joins Memorial Sloan Kettering Innovation Hub for Precision Oncology Aug 19, 2021 TERT Promoter Mutations Linked to Higher Recurrence Risk in Oral Cavity Cancers Premium Aug 3, 2021 SpringWorks, MSK Collaborate to Study MEK Inhibitor in Certain Solid Tumors Jul 13, 2021 Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing Apr 15, 2021 AACR Project GENIE Enables Analysis of Growing Actionability, Disparities in Precision Oncology Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
